Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anand George Andrews"'
Autor:
Parth Sharma, Josh Thomas Georgy, Anand George Andrews, Ajoy Oommen John, Anjana Joel, Raju Titus Chacko, Prasanna Samuel Premkumar, Ashish Singh
Publikováno v:
Supportive Care in Cancer. 30:5519-5526
Dose-dense chemotherapy improves survival but with increased toxicity and treatment-related cost. We report the prevalence of anemia and the possible risk factors associated with chemotherapy-related anemia and determine the cost and time-delay assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b68508a7dbbdbf0540a4a5e3dea5693f
https://doi.org/10.1007/s00520-022-06970-2
https://doi.org/10.1007/s00520-022-06970-2
Autor:
Ashish Singh, Josh Thomas Georgy, Ajoy Oommen John, Divya Bala Thumaty, Anjana Joel, Parth Sharma, Anand George Andrews, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko
Purpose Carboplatin-containing treatment regimens in early TNBC have shown improved pCR(pathological complete response) and better EFS(event-free survival) but at the expense of increased toxicity, often leading to compromised delivery of planned tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::399447018f6ab125e3c0ff173ec68745
https://doi.org/10.21203/rs.3.rs-1519744/v1
https://doi.org/10.21203/rs.3.rs-1519744/v1
Autor:
Parth Sharma, Josh Thomas Georgy, Anand George Andrews, Ajoy Oommen John, Anjana Joel, Raju Titus Chacko, Ashish Singh
Purpose: Dose dense chemotherapy improves survival but also increases toxicity and treatment related cost. Here we report the prevalence of anemia, understand the risk factors of chemotherapy related anemia and determine the cost and time-delay assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19bd7ae000efe7e5814b772a9754de9d
https://doi.org/10.21203/rs.3.rs-990324/v1
https://doi.org/10.21203/rs.3.rs-990324/v1
Publikováno v:
ecancermedicalscience
Palbociclib is a cyclin dependent kinase (CDK) 4/6 inhibitor that is indicated in combination with an aromatase inhibitor for first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2 -negative advanced or metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725d16639a4e66c383d9e27677c9930f
http://europepmc.org/articles/PMC8241445
http://europepmc.org/articles/PMC8241445